北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学临床肿瘤学院  > 胸部肿瘤内科  > 期刊论文
学科主题: 临床医学
题名:
A Randomized Phase 3 Trial Comparing Pemetrexed/Carboplatin and Docetaxel/Carboplatin as First-Line Treatment for Advanced, Nonsquamous Non-small Cell Lung Cancer
作者: Rodrigues-Pereira, Jose2; Kim, Joo-Hang3; Magallanes, Manuel4; Lee, Dae Ho5; Wang, Jie6,7; Ganju, Vinod8; Martinez-Barrera, Luis9; Barraclough, Helen10; van Kooten, Maximiliano10; Orlando, Mauro1
关键词: Carboplatin ; Docetaxel ; First-line therapy ; Non-small cell lung carcinoma ; Nonsquamous ; Pemetrexed
刊名: JOURNAL OF THORACIC ONCOLOGY
发表日期: 2011-11-01
DOI: 10.1097/JTO.0b013e318226b5fa
卷: 6, 期:11, 页:1907-1914
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology ; Respiratory System
研究领域[WOS]: Oncology ; Respiratory System
关键词[WOS]: CLINICAL-PRACTICE GUIDELINES ; CISPLATIN PLUS GEMCITABINE ; RISK-BENEFIT ANALYSIS ; 2ND EDITION ; FOLLOW-UP ; STAGE-IV ; CARBOPLATIN ; DOCETAXEL ; CHEMOTHERAPY ; TOXICITY
英文摘要:

Introduction: This study compared survival without toxicity in patients with advanced, nonsquamous non-small cell lung cancer who were treated with first-line pemetrexed/carboplatin or docetaxel/carboplatin.

Methods: This multicenter, open-label, parallel-group, phase 3 trial comprised patients randomized (1:1) to pemetrexed/carboplatin (n = 128) or docetaxel/carboplatin (n = 132). Patients received treatment on day 1 of each 21-day cycle (maximum of six cycles). Treatment included carboplatin (area under the curve = 5 mg/ml x min) and pemetrexed (500 mg/m(2)) or docetaxel (75 mg/m(2)). The primary outcome measure, survival without treatment-emergent grade 3/4 toxicity, was defined as the time from randomization to the first treatment-emergent grade 3/4 adverse event or death and was analyzed using a log-rank test. The analysis population included 106 patients in the pemetrexed/carboplatin (Pem/Carb) group and 105 patients in the docetaxel/carboplatin (Doc/Carb) group.

Results: Survival without treatment-emergent grade 3/4 toxicity was significantly longer in the Pem/Carb versus the Doc/Carb group (log-rank p < 0.001; median survival without treatment-emergent grade 3/4 toxicity: 3.2 versus 0.7 months; adjusted hazard ratio = 0.45 [95% confidence interval: 0.34-0.61]). Overall survival was similar in the Pem/Carb versus the Doc/Carb group (log-rank p = 0.934; median survival: 14.9 versus 14.7 months; adjusted hazard ratio = 0.93 [95% confidence interval: 0.66-1.32]). Compared with the Doc/Carb group, fewer patients in the Pem/Carb group experienced grade 3/4 drug-related, treatment-emergent neutropenia, leukopenia, or febrile neutropenia, and more patients experienced anemia and thrombocytopenia. There were three study drug-related deaths during treatment in each group.

Conclusions: The favorable benefit-to-risk profile of pemetrexed/ carboplatin suggests that pemetrexed/carboplatin is an appropriate first-line treatment option for chemona ve patients with advanced, nonsquamous non-small cell lung cancer.

语种: 英语
项目资助者: Eli Lilly ; Eli Lilly Australia ; Eli Lilly and Company
WOS记录号: WOS:000296700400018
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/51291
Appears in Collections:北京大学临床肿瘤学院_胸部肿瘤内科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Mil Hosp Mexico, Dept Med Oncol, Mexico City, DF, Mexico
2.Beijing Canc Hosp & Inst, Beijing, Peoples R China
3.INER, Dept Med Oncol, Mexico City, DF, Mexico
4.Eli Lilly Australia Pty Ltd, Sydney, NSW, Australia
5.Eli Lilly Interamer Inc, Buenos Aires, DF, Argentina
6.Inst Canc Arnaldo Vieira de Carvalho, Sao Paulo, Brazil
7.Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Seoul, South Korea
8.Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
9.Peking Univ, Sch Oncol, Dept Thorac Med Oncol, Beijing 100871, Peoples R China
10.Frankston Private, Peninsula Oncol Ctr, Dept Oncol, Frankston, Vic, Australia

Recommended Citation:
Rodrigues-Pereira, Jose,Kim, Joo-Hang,Magallanes, Manuel,et al. A Randomized Phase 3 Trial Comparing Pemetrexed/Carboplatin and Docetaxel/Carboplatin as First-Line Treatment for Advanced, Nonsquamous Non-small Cell Lung Cancer[J]. JOURNAL OF THORACIC ONCOLOGY,2011,6(11):1907-1914.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Rodrigues-Pereira, Jose]'s Articles
[Kim, Joo-Hang]'s Articles
[Magallanes, Manuel]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Rodrigues-Pereira, Jose]‘s Articles
[Kim, Joo-Hang]‘s Articles
[Magallanes, Manuel]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace